Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7770548 | 0.79 | CA12 (0.33) | CA12CA1CA9CA2 | |
| SCHEMBL18754884 | 0.78 | — | — | |
| SCHEMBL11598492 | 0.75 | — | — | |
| SCHEMBL2524017 | 0.73 | TSHR (0.35) | CA12CA1CA9CA2 | |
| SCHEMBL5167303 | 0.72 | DNM1 (0.31) | CA12CA1CA9 | |
| SCHEMBL13570339 | 0.72 | DNM1 (0.31) | CA12CA1CA9 | |
| SCHEMBL11667395 | 0.72 | MMP1 (0.32) | CA12CA1CA9 | |
| SCHEMBL14472702 | 0.72 | DNM1 (0.42) | CA12CA1CA9CA2PLA2G1B | |
| SCHEMBL7988589 | 0.70 | CA12 (0.37) | CA12CA1CA9CA2 | |
| SCHEMBL28831350 | 0.70 | FDPS (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342058-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | CA12 523/4885CA1 779/4885CA9 368/4885 |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | METAP2, FAP, FOLH1 | CA12 523/4885CA1 779/4885CA9 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.